Defining the energetic basis for a conformational switch mediating ligand-independent activation of mutant estrogen receptors in breast cancer Journal Article


Authors: Mayne, C. G.; Toy, W.; Carlson, K. E.; Bhatt, T.; Fanning, S. W.; Greene, G. L.; Katzenellenbogen, B. S.; Chandarlapaty, S.; Katzenellenbogen, J. A.; Tajkhorshid, E.
Article Title: Defining the energetic basis for a conformational switch mediating ligand-independent activation of mutant estrogen receptors in breast cancer
Abstract: Although most primary estrogen receptor (ER)-positive breast cancers respond well to endocrine therapies, many relapse later as metastatic disease due to endocrine therapy resistance. Over one third of these are associated with mutations in the ligand-binding domain (LBD) that activate the receptor independent of ligand. We have used an array of advanced computational techniques rooted in molecular dynamics simulations, in concert with and validated by experiments, to characterize the molecular mechanisms by which specific acquired somatic point mutations give rise to ER constitutive activation. By comparing structural and energetic features of constitutively active mutants and ligand-bound forms of ER-LBD with unliganded wild-type (WT) ER, we characterize a spring force originating from strain in the Helix 11-12 loop of WT-ER, opposing folding of Helix 12 into the active conformation and keeping WT-ER off and disordered, with the ligand-binding pocket open for rapid ligand binding. We quantify ways in which this spring force is abrogated by activating mutations that latch (Y537S) or relax (D538G) the folded form of the loop, enabling formation of the active conformation without ligand binding. We also identify a new ligand-mediated hydrogen-bonding network that stabilizes the active, ligand-bound conformation of WT-ER LBD, and similarly stabilizes the active conformation of the ER mutants in the hormone-free state. Implications: Our investigations provide deep insight into the energetic basis for the structural mechanisms of receptor activation through mutation, exemplified here with ER in endocrine-resistant metastatic breast cancers, with potential application to other dysregulated receptor signaling due to driver mutations. © 2021 American Association for Cancer Research.
Journal Title: Molecular Cancer Research
Volume: 19
Issue: 9
ISSN: 1541-7786
Publisher: American Association for Cancer Research  
Date Published: 2021-09-01
Start Page: 1559
End Page: 1570
Language: English
DOI: 10.1158/1541-7786.Mcr-20-1017
PUBMED: 34021071
PROVIDER: scopus
PMCID: PMC8419021
DOI/URL:
Notes: Article -- Export Date: 1 October 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Weiyi Toy
    19 Toy
  2. Trusha   Bhatt
    6 Bhatt